ImmuPharma plc (LON:IMM – Get Free Report) fell 5.3% during mid-day trading on Wednesday . The company traded as low as GBX 5.04 ($0.06) and last traded at GBX 5.59 ($0.07). 46,394,512 shares traded hands during trading, an increase of 88% from the average session volume of 24,729,924 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Trading Up 7.4 %
The firm has a market cap of £24.15 million, a P/E ratio of -580.00 and a beta of 1.53. The company’s fifty day moving average price is GBX 2.06 and its two-hundred day moving average price is GBX 1.83.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- The How And Why of Investing in Oil Stocks
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What is an Earnings Surprise?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
